Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Verteporfin.

L J Scott1, K L Goa

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|April 8, 2000
PubMed
Summary
This summary is machine-generated.

Verteporfin photodynamic therapy (PDT) effectively treats age-related macular degeneration (AMD) by targeting abnormal blood vessels. Repeated treatments improved or maintained vision in most patients with subfoveal choroidal neovascularisation (CNV).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of traumatic brain injury amongst secondary school students in England: A retrospective cohort study using electronic health records.

Injury·2026
Same author

Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Drugs·2020
Same author

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Drugs·2020
Same author

Systematic review of interventions for the prevention and treatment of postoperative urinary retention.

BJS open·2019
Same author

Correction to: The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research.

Pilot and feasibility studies·2018
Same author

The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research.

Pilot and feasibility studies·2018
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Ophthalmology
  • Oncology
  • Pharmacology

Background:

  • Verteporfin is a photosensitizer used in photodynamic therapy (PDT).
  • It targets cells with high low-density lipoprotein (LDL) receptor expression, like neovascular endothelial cells.
  • PDT with verteporfin selectively damages these cells, causing thrombus formation and vessel occlusion.

Purpose of the Study:

  • To evaluate the efficacy and safety of verteporfin therapy for subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD).

Main Methods:

  • Two large multicentre, placebo-controlled, double-blind trials were conducted.
  • Patients received repeated applications of verteporfin therapy (6 mg/m2) with low-intensity light.
  • Visual acuity (VA) was assessed at 1-year follow-up.

Related Experiment Videos

Main Results:

  • The majority of patients with subfoveal CNV secondary to AMD showed improved or maintained visual acuity after 1 year.
  • In a subgroup with predominantly classic CNV, 67.3% of verteporfin-treated eyes had <15-letter VA loss versus 39.3% for placebo.
  • Verteporfin therapy was generally well tolerated.

Conclusions:

  • Verteporfin therapy is an effective treatment for subfoveal CNV secondary to AMD.
  • Repeated treatments demonstrate significant visual acuity benefits, particularly in predominantly classic CNV.
  • The treatment is well-tolerated with manageable adverse events like photosensitivity.